Axsome Therapeutics, Inc. reported significant financial growth in its latest quarterly filing, with total revenues reaching $171.0 million for the three months ended September 30, 2025, compared to $104.8 million for the same period in 2024. For the nine months ending September 30, 2025, revenues totaled $442.5 million, up from $266.9 million in the prior year. The increase in revenue was primarily driven by higher product sales, particularly from its commercialized products Auvelity, Sunosi, and the recently launched Symbravo, which collectively contributed to a net loss of $47.2 million for the quarter, a decrease from a loss of $64.6 million in the same quarter last year.
The company experienced notable changes in its operational metrics, with product sales for Auvelity increasing to $136.1 million in Q3 2025 from $80.4 million in Q3 2024, and Sunosi sales rising to $31.6 million from $23.4 million in the same timeframe. The launch of Symbravo in June 2025 added $2.1 million in sales for the quarter. Axsome's total operating expenses also rose, amounting to $217.1 million for the quarter, compared to $167.4 million in the previous year, largely due to increased selling, general, and administrative expenses associated with the expansion of its commercial activities.
Strategically, Axsome has made significant advancements, including the successful launch of Symbravo and the ongoing commercialization of Auvelity and Sunosi. The company has also entered into a licensing agreement with Pharmanovia to market Sunosi in Europe and certain Middle Eastern countries, which is expected to enhance its market presence. As of September 30, 2025, Axsome had 816 full-time employees, reflecting its growth in personnel to support its expanding operations.
Looking ahead, Axsome anticipates continued investment in its product pipeline and commercialization efforts, which may lead to increased operating expenses. The company believes its existing cash reserves, totaling $325.3 million as of September 30, 2025, will be sufficient to fund operations for at least the next twelve months. However, Axsome acknowledges the potential need for additional financing to support its ongoing development and commercialization activities, particularly as it navigates the complexities of regulatory approvals and market competition. The company remains focused on achieving profitability through the successful commercialization of its products and the advancement of its product candidates.
About Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing novel oral therapies for central nervous system (CNS) disorders. Its portfolio includes FDA-approved products for major depressive disorder, excessive daytime sleepiness, and acute migraine treatment, alongside late-stage candidates for Alzheimer’s agitation, narcolepsy, fibromyalgia, and other CNS conditions. Axsome leverages proprietary formulation technologies and targets underserved CNS markets with high unmet medical needs, primarily serving patients and healthcare providers in the U.S.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.